Lazard Asset Management LLC Sells 116,018 Shares of Phreesia, Inc. (NYSE:PHR)

Lazard Asset Management LLC decreased its holdings in shares of Phreesia, Inc. (NYSE:PHR) by 23.7% in the 1st quarter, Holdings Channel.com reports. The firm owned 372,694 shares of the company’s stock after selling 116,018 shares during the quarter. Lazard Asset Management LLC’s holdings in Phreesia were worth $8,918,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. International Assets Investment Management LLC raised its position in shares of Phreesia by 1,987.3% during the fourth quarter. International Assets Investment Management LLC now owns 1,482 shares of the company’s stock valued at $34,000 after buying an additional 1,411 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Phreesia by 4.4% in the 4th quarter. Vanguard Group Inc. now owns 4,628,441 shares of the company’s stock worth $107,148,000 after acquiring an additional 194,035 shares during the period. Champlain Investment Partners LLC acquired a new stake in shares of Phreesia during the 1st quarter worth approximately $29,941,000. Brown Advisory Inc. increased its position in shares of Phreesia by 22.2% during the fourth quarter. Brown Advisory Inc. now owns 3,950,356 shares of the company’s stock valued at $91,451,000 after purchasing an additional 716,374 shares during the period. Finally, Blair William & Co. IL raised its stake in shares of Phreesia by 42.6% in the first quarter. Blair William & Co. IL now owns 752,700 shares of the company’s stock valued at $18,012,000 after purchasing an additional 224,950 shares in the last quarter. Institutional investors and hedge funds own 92.10% of the company’s stock.

Phreesia Stock Performance

Phreesia stock traded up $0.35 on Friday, reaching $24.77. The company’s stock had a trading volume of 394,560 shares, compared to its average volume of 440,717. The business’s fifty day moving average price is $21.30 and its 200 day moving average price is $23.12. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.76 and a quick ratio of 1.76. Phreesia, Inc. has a twelve month low of $12.05 and a twelve month high of $32.11.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Thursday, May 30th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.16. The business had revenue of $101.20 million for the quarter, compared to the consensus estimate of $100.94 million. Phreesia had a negative net margin of 31.87% and a negative return on equity of 46.89%. The firm’s quarterly revenue was up 20.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.70) EPS. As a group, equities research analysts forecast that Phreesia, Inc. will post -1.16 EPS for the current year.

Insider Transactions at Phreesia

In related news, CEO Chaim Indig sold 2,644 shares of the business’s stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $23.74, for a total value of $62,768.56. Following the completion of the transaction, the chief executive officer now owns 1,219,361 shares in the company, valued at approximately $28,947,630.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Chaim Indig sold 2,644 shares of Phreesia stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $23.74, for a total value of $62,768.56. Following the completion of the sale, the chief executive officer now directly owns 1,219,361 shares in the company, valued at $28,947,630.14. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Mark Douglas Smith sold 7,000 shares of the company’s stock in a transaction dated Thursday, July 18th. The shares were sold at an average price of $25.00, for a total transaction of $175,000.00. Following the transaction, the director now owns 30,653 shares in the company, valued at $766,325. The disclosure for this sale can be found here. Over the last three months, insiders have sold 15,506 shares of company stock worth $375,299. Corporate insiders own 5.80% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on PHR. Stephens reiterated an “overweight” rating and set a $28.00 price target on shares of Phreesia in a research note on Friday, May 31st. Canaccord Genuity Group lowered their target price on shares of Phreesia from $37.00 to $34.00 and set a “buy” rating on the stock in a research note on Friday, May 31st. JMP Securities restated a “market outperform” rating and set a $30.00 price target on shares of Phreesia in a research note on Friday, May 31st. KeyCorp decreased their price objective on Phreesia from $27.00 to $25.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Finally, Truist Financial reissued a “buy” rating and issued a $29.00 target price on shares of Phreesia in a report on Monday, July 1st. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $30.54.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.